COMMUNIQUÉS West-GlobeNewswire

Transactions under Novozymes’ stock buyback program

19/02/2018 - 16:04

Please read the full announcement in the attached PDF http://prlibrary-eu.nasdaq.com/Resource/Download/fe173723-e6ca-4eb1-9177-48696a6c841e

Notice to convene annual general meeting 2018 of GN Store Nord

19/02/2018 - 14:16

Please find enclosed notice of GN Store Nord A/S’ annual general meeting 2018, including the complete proposals for the agenda. For further information, please contact: Investors and analysts Peter Justesen VP – [...]

The American Health Council Names Gilberto Alvarado, MSN, CNP, FNP-BC, BSN, RN to Board of Nurses

19/02/2018 - 14:00

NEW YORK, Feb. 19, 2018 (GLOBE NEWSWIRE) -- Gilberto “Gil” Alvarado, MSN, CNP, FNP-BC, BSN, RN is named to the American Health Council’s Board of Nurses for his impeccable contributions to the nursing field, both in a [...]

Alder BioPharmaceuticals® to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial and Operating Results

19/02/2018 - 14:00

BOTHELL, Wash., Feb. 19, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR ), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

19/02/2018 - 13:01

FIT Biotech Oy Company release February 19, 2018 at 2:00 PM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on December 22, 2017 [...]

Novo Nordisk A/S - Share repurchase programme

19/02/2018 - 12:12

Bagsværd, Denmark, 19 February 2018 - On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]

Notice of Annual General Meeting

19/02/2018 - 09:04

Valby, Denmark, 2018-02-19 09:04 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 19 February 2018 – Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: Tuesday, 20 March 2018 at 10:00 am The [...]

Oasmia Pharmaceutical’s Docecal program achieves significant development milestone

19/02/2018 - 08:30

Oasmia Pharmaceutical AB announces that all patients have been treated in the two ongoing studies with Docecal in metastatic breast cancer. Uppsala, Sweden, February 19, 2018 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a [...]

Bone Therapeutics SA completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB®

19/02/2018 - 07:01

Press release Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB ® Efficacy and safety results expected in mid-2019 Promising interim efficacy and safety data already reported [...]

Bone Therapeutics annonce le recrutement du dernier patient de son étude de Phase IIA dans la fusion vertébrale avec ALLOB®

19/02/2018 - 07:01

Communiqué de presse Bone Therapeutics annonce le recrutement du dernier patient de son étude de Phase IIA dans la fusion vertébrale avec ALLOB ® Résultats d'efficacité et de sécurité attendus mi-2019 Données [...]

MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California

19/02/2018 - 00:00

LA JOLLA, Calif., Feb. 18, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV ) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875 [...]

New Data in Pediatric Patients with Axillary Hyperhidrosis Presented During Late-Breaking Research Forum at the 76th Annual Meeting of the American Academy of Dermatology

18/02/2018 - 00:30

SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM ), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the [...]

AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting

17/02/2018 - 23:00

SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB ), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation [...]

TLC Files Registration Statement for Proposed Initial Public Offering

17/02/2018 - 10:06

TAIPEI, Taiwan, Feb. 17, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO) (TLC), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel [...]

Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego

17/02/2018 - 10:01

MOR106 was generally well tolerated in atopic dermatitis (AD) patients 83% of patients (5 out of 6) at the highest dose reached at least 50% improvement per the atopic dermatitis area and severity index (EASI-50) at [...]

ChromaDex Chairman Stephen Allen Will Retire from Board of Directors

16/02/2018 - 22:30

IRVINE, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ: CDXC ), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age is announcing [...]

OncBioMune Provides Update on Market Activity

16/02/2018 - 22:23

BATON ROUGE, La., Feb. 16, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary [...]

Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis

16/02/2018 - 22:06

Two thirds of patients on Cosentyx ® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows[1] Findings show absolute PASI <=1/<=2/<=3 responses were [...]

Pernix Therapeutics Announces Launch of Authorized Generic Version of Treximet® by Company’s Subsidiary, Macoven Pharmaceuticals

16/02/2018 - 22:01

MORRISTOWN, N.J., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX ), a specialty pharmaceutical company, today announced the launch of an authorized generic version of Treximet® ( [...]